284. ダイアモンド・ブラックファン貧血 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 36 / 薬物数 : 95 - (DrugBank : 34) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 126
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
(S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazo
Shire Development LLC
2010 Phase 2 EUCTR2010-019645-25-GB Italy;Thailand;Turkey;United Kingdom;United States;
(S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide
Shire Development LLC
2010 Phase 2 EUCTR2010-019645-25-GB Italy;Thailand;Turkey;United Kingdom;United States;
(S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-m
Shire Development LLC
2012 Phase 2 EUCTR2011-006322-25-GB Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
(S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide
Shire Development LLC
2012 Phase 2 EUCTR2011-006322-25-GB Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
Abatacept
Emory University
2014 Phase 1 NCT01917708 United States;
Alefacept
Emory University
2010 - NCT01319851 United States;
Alemtuzumab
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03653338 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
Allogeneic bone marrow transplantation
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
Allogeneic hematopoietic stem cell transplantation
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
Alpha beta depletion
Mitchell Cairo
2020 Phase 2 NCT04099966 United States;
Anti-thymocyte globulin
Masonic Cancer Center, University of Minnesota
2000 Phase 2/Phase 3 NCT00176878 United States;
1999 - NCT00290628 United States;
University of California, San Francisco
2000 Phase 1/Phase 2 NCT00305708 United States;
Antithymocyte globulin
National Heart, Lung, and Blood Institute (NHLBI)
1998 Phase 2 NCT00001749 United States;
BPX-501 T cells
Bellicum Pharmaceuticals
2014 Phase 2 NCT02065869 Germany;Italy;Spain;United Kingdom;United States;
Bone marrow transplantation
Stanford University
2009 Phase 2 NCT00957931 United States;
Busulfan
Masonic Cancer Center, University of Minnesota
2000 Phase 2/Phase 3 NCT00176878 United States;
1999 - NCT00290628 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
Busulfan, Cyclophosphamide, ATG, GCSF
Masonic Cancer Center, University of Minnesota
2002 Phase 2/Phase 3 NCT00176852 United States;
Busulfan, Fludarabine, ATG, TLI
Masonic Cancer Center, University of Minnesota
2002 Phase 2/Phase 3 NCT00176852 United States;
CD3/CD19 depleted leukocytes
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03653338 United States;
CD34 Stem Cell Selection Therapy
Diane George
2013 Phase 1/Phase 2 NCT01966367 United States;
CD45RA depleted leukocytes
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03653338 United States;
Campath, Fludarabine, Cyclophosphamide
Masonic Cancer Center, University of Minnesota
2002 Phase 2/Phase 3 NCT00176852 United States;
Cyclophosphamide
Masonic Cancer Center, University of Minnesota
1999 - NCT00290628 United States;
Cyclophosphamide Dose Level 1
Children's Hospital Los Angeles
2007 Phase 2 NCT02512679 -
Cyclophosphamide Dose Level 2
Children's Hospital Los Angeles
2007 Phase 2 NCT02512679 -
Cyclophosphamide Dose Level 3
Children's Hospital Los Angeles
2007 Phase 2 NCT02512679 -
Cyclophosphamide Dose Level 4
Children's Hospital Los Angeles
2007 Phase 2 NCT02512679 -
Cyclosporine
Masonic Cancer Center, University of Minnesota
1999 - NCT00290628 United States;
National Heart, Lung, and Blood Institute (NHLBI)
1998 Phase 2 NCT00001749 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
DFO
Novartis Pharma Services AG
2008 Phase 2 EUCTR2007-000766-20-GB Italy;United Kingdom;
Daclizumab
Neal Young, M.D.
1999 Phase 2 NCT00001962 United States;
Deferasirox
Novartis
2007 Phase 4 NCT00673608 Australia;
Novartis Pharma Services AG
2008 Phase 2 EUCTR2007-000766-20-GB Italy;United Kingdom;
Novartis Pharmaceuticals
2005 Phase 3 NCT00235391 Australia;Belgium;Canada;Germany;Greece;Italy;Netherlands;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Deferitazole
Shire Development LLC
2012 Phase 2 EUCTR2011-006322-25-GB Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
Deferoxamine
Novartis Pharma Services AG
2008 Phase 2 EUCTR2007-000766-20-GB Italy;United Kingdom;
Desferal
Novartis Pharma Services AG
2008 Phase 2 EUCTR2007-000766-20-GB Italy;United Kingdom;
Eltrombopag
National Heart, Lung, and Blood Institute (NHLBI)
2020 Phase 1/Phase 2 NCT04269889 United States;
Enriched Hematopoetic Stem Cell Infusion
Talaris Therapeutics Inc.
2011 Phase 1/Phase 2 NCT01419704 United States;
FBS0701 CAPSULE
FERROKIN BIOSCIENCES INC.
2012 - EUCTR2011-006322-25-IT Italy;United Kingdom;United States;
2012 - EUCTR2011-005675-16-IT Canada;Italy;Lebanon;Turkey;United States;
FBS0701 Capsule
FERROKIN BIOSCIENCES INC.
2010 - EUCTR2010-019645-25-IT Italy;United Kingdom;
FBS0701/SSP004184
FERROKIN BIOSCIENCES INC.
2012 - EUCTR2011-006322-25-IT Italy;United Kingdom;United States;
Filgrastim
Masonic Cancer Center, University of Minnesota
1999 - NCT00290628 United States;
Fludarabine
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03653338 United States;
Fludarabine monophosphate
Masonic Cancer Center, University of Minnesota
2000 Phase 2/Phase 3 NCT00176878 United States;
Fludarabine phosphate
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
G-CSF
National Heart, Lung, and Blood Institute (NHLBI)
2001 Phase 2 NCT00011505 United States;
Human Placental Derived Stem Cell
New York Medical College
2013 Phase 1 NCT01586455 United States;
Hydroxyurea
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03653338 United States;
ICL670
Novartis Pharma Services AG
2008 Phase 2 EUCTR2007-000766-20-GB Italy;United Kingdom;
Iron chelating agents
FERROKIN BIOSCIENCES INC.
2012 - EUCTR2011-005675-16-IT Canada;Italy;Lebanon;Turkey;United States;
L-leucine
Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogache
2014 Phase 2 NCT02386267 Russian Federation;
Lenalidomide
Jason Robert Gotlib
2009 Phase 1 NCT01034592 United States;
Leucine
Northwell Health
2013 Phase 1/Phase 2 NCT01362595 United States;
Leukapheresis
National Heart, Lung, and Blood Institute (NHLBI)
2001 Phase 2 NCT00011505 United States;
Melphalan
Masonic Cancer Center, University of Minnesota
1999 - NCT00290628 United States;
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
Mesenchymal Stromal Cells
Stanford University
2009 Phase 2 NCT00957931 United States;
Methotrexate
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
Methylprednisolone
Masonic Cancer Center, University of Minnesota
1999 - NCT00290628 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
Mycophenolate mofetil
Masonic Cancer Center, University of Minnesota
1999 - NCT00290628 United States;
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
Myeloablative Preparative Regimen
Masonic Cancer Center, University of Minnesota
2014 - NCT02179359 United States;
Peripheral blood stem cell transplantation
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
Radiation therapy
Masonic Cancer Center, University of Minnesota
1999 - NCT00290628 United States;
Reduced Intensity Preparative Regimen
Masonic Cancer Center, University of Minnesota
2014 - NCT02179359 United States;
Reduced Toxicity Ablative Regimen
Masonic Cancer Center, University of Minnesota
2014 - NCT02179359 United States;
Rimiducid
Bellicum Pharmaceuticals
2017 Phase 1/Phase 2 NCT03733249 Italy;Saudi Arabia;United Kingdom;
2014 Phase 2 NCT02065869 Germany;Italy;Spain;United Kingdom;United States;
Rituximab
National Heart, Lung, and Blood Institute (NHLBI)
2005 Phase 2 NCT00229619 United States;
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03653338 United States;
Rivogenlecleucel
Bellicum Pharmaceuticals
2017 Phase 1/Phase 2 NCT03733249 Italy;Saudi Arabia;United Kingdom;
SSP-004184 100 mg Capsule
Shire Development LLC
2010 Phase 2 EUCTR2010-019645-25-GB Italy;Thailand;Turkey;United Kingdom;United States;
SSP-004184 250 mg Capsule
Shire Development LLC
2010 Phase 2 EUCTR2010-019645-25-GB Italy;Thailand;Turkey;United Kingdom;United States;
SSP-004184 375 mg Capsule
Shire Development LLC
2010 Phase 2 EUCTR2010-019645-25-GB Italy;Thailand;Turkey;United Kingdom;United States;
SSP-004184 50 mg Capsule
Shire Development LLC
2010 Phase 2 EUCTR2010-019645-25-GB Italy;Thailand;Turkey;United Kingdom;United States;
SSP-004184 500 mg Capsule
Shire Development LLC
2010 Phase 2 EUCTR2010-019645-25-GB Italy;Thailand;Turkey;United Kingdom;United States;
SSP-004184AQ 100 mg Capsule
Shire Development LLC
2012 Phase 2 EUCTR2011-006322-25-GB Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
SSP-004184AQ 200 mg Capsule
Shire Development LLC
2012 Phase 2 EUCTR2011-006322-25-GB Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
SSP-004184AQ 250 mg Capsule
Shire Development LLC
2012 Phase 2 EUCTR2011-006322-25-GB Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
SSP-004184AQ 375 mg Capsule
Shire Development LLC
2012 Phase 2 EUCTR2011-006322-25-GB Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
SSP-004184AQ 50 mg Capsule
Shire Development LLC
2012 Phase 2 EUCTR2011-006322-25-GB Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
Sotatercept with prednisone boost
Northwell Health
2012 Phase 1/Phase 2 NCT01464164 United States;
Stem cell infusion
Masonic Cancer Center, University of Minnesota
2002 Phase 2/Phase 3 NCT00176852 United States;
Stem cell transplant
Masonic Cancer Center, University of Minnesota
2000 Phase 2/Phase 3 NCT00176878 United States;
Tacrolimus
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
Thiotepa
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03653338 United States;
Thiotepa--escalated dose
University of Florida
2018 Phase 1/Phase 2 NCT03513328 United States;
Thiotepa--single daily dose
University of Florida
2018 Phase 1/Phase 2 NCT03513328 United States;
Total lymphoid irradiation
Masonic Cancer Center, University of Minnesota
2000 Phase 2/Phase 3 NCT00176878 United States;
Trifluoperazine
Adrianna Vlachos
2019 Phase 1/Phase 2 NCT03966053 United States;
Umbilical cord blood transplantation
Masonic Cancer Center, University of Minnesota
1999 - NCT00290628 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
Shire Development LLC
2010 Phase 2 EUCTR2010-019645-25-GB Italy;Thailand;Turkey;United Kingdom;United States;
(S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide
Shire Development LLC
2010 Phase 2 EUCTR2010-019645-25-GB Italy;Thailand;Turkey;United Kingdom;United States;
(S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-m
Shire Development LLC
2012 Phase 2 EUCTR2011-006322-25-GB Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
(S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide
Shire Development LLC
2012 Phase 2 EUCTR2011-006322-25-GB Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
Abatacept
Emory University
2014 Phase 1 NCT01917708 United States;
Alefacept
Emory University
2010 - NCT01319851 United States;
Alemtuzumab
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03653338 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
Allogeneic bone marrow transplantation
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
Allogeneic hematopoietic stem cell transplantation
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
Alpha beta depletion
Mitchell Cairo
2020 Phase 2 NCT04099966 United States;
Anti-thymocyte globulin
Masonic Cancer Center, University of Minnesota
2000 Phase 2/Phase 3 NCT00176878 United States;
1999 - NCT00290628 United States;
University of California, San Francisco
2000 Phase 1/Phase 2 NCT00305708 United States;
Antithymocyte globulin
National Heart, Lung, and Blood Institute (NHLBI)
1998 Phase 2 NCT00001749 United States;
BPX-501 T cells
Bellicum Pharmaceuticals
2014 Phase 2 NCT02065869 Germany;Italy;Spain;United Kingdom;United States;
Bone marrow transplantation
Stanford University
2009 Phase 2 NCT00957931 United States;
Busulfan
Masonic Cancer Center, University of Minnesota
2000 Phase 2/Phase 3 NCT00176878 United States;
1999 - NCT00290628 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
Busulfan, Cyclophosphamide, ATG, GCSF
Masonic Cancer Center, University of Minnesota
2002 Phase 2/Phase 3 NCT00176852 United States;
Busulfan, Fludarabine, ATG, TLI
Masonic Cancer Center, University of Minnesota
2002 Phase 2/Phase 3 NCT00176852 United States;
CD3/CD19 depleted leukocytes
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03653338 United States;
CD34 Stem Cell Selection Therapy
Diane George
2013 Phase 1/Phase 2 NCT01966367 United States;
CD45RA depleted leukocytes
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03653338 United States;
Campath, Fludarabine, Cyclophosphamide
Masonic Cancer Center, University of Minnesota
2002 Phase 2/Phase 3 NCT00176852 United States;
Cyclophosphamide
Masonic Cancer Center, University of Minnesota
1999 - NCT00290628 United States;
Cyclophosphamide Dose Level 1
Children's Hospital Los Angeles
2007 Phase 2 NCT02512679 -
Cyclophosphamide Dose Level 2
Children's Hospital Los Angeles
2007 Phase 2 NCT02512679 -
Cyclophosphamide Dose Level 3
Children's Hospital Los Angeles
2007 Phase 2 NCT02512679 -
Cyclophosphamide Dose Level 4
Children's Hospital Los Angeles
2007 Phase 2 NCT02512679 -
Cyclosporine
Masonic Cancer Center, University of Minnesota
1999 - NCT00290628 United States;
National Heart, Lung, and Blood Institute (NHLBI)
1998 Phase 2 NCT00001749 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
DFO
Novartis Pharma Services AG
2008 Phase 2 EUCTR2007-000766-20-GB Italy;United Kingdom;
Daclizumab
Neal Young, M.D.
1999 Phase 2 NCT00001962 United States;
Deferasirox
Novartis
2007 Phase 4 NCT00673608 Australia;
Novartis Pharma Services AG
2008 Phase 2 EUCTR2007-000766-20-GB Italy;United Kingdom;
Novartis Pharmaceuticals
2005 Phase 3 NCT00235391 Australia;Belgium;Canada;Germany;Greece;Italy;Netherlands;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Deferitazole
Shire Development LLC
2012 Phase 2 EUCTR2011-006322-25-GB Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
Deferoxamine
Novartis Pharma Services AG
2008 Phase 2 EUCTR2007-000766-20-GB Italy;United Kingdom;
Desferal
Novartis Pharma Services AG
2008 Phase 2 EUCTR2007-000766-20-GB Italy;United Kingdom;
Eltrombopag
National Heart, Lung, and Blood Institute (NHLBI)
2020 Phase 1/Phase 2 NCT04269889 United States;
Enriched Hematopoetic Stem Cell Infusion
Talaris Therapeutics Inc.
2011 Phase 1/Phase 2 NCT01419704 United States;
FBS0701 CAPSULE
FERROKIN BIOSCIENCES INC.
2012 - EUCTR2011-006322-25-IT Italy;United Kingdom;United States;
2012 - EUCTR2011-005675-16-IT Canada;Italy;Lebanon;Turkey;United States;
FBS0701 Capsule
FERROKIN BIOSCIENCES INC.
2010 - EUCTR2010-019645-25-IT Italy;United Kingdom;
FBS0701/SSP004184
FERROKIN BIOSCIENCES INC.
2012 - EUCTR2011-006322-25-IT Italy;United Kingdom;United States;
Filgrastim
Masonic Cancer Center, University of Minnesota
1999 - NCT00290628 United States;
Fludarabine
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03653338 United States;
Fludarabine monophosphate
Masonic Cancer Center, University of Minnesota
2000 Phase 2/Phase 3 NCT00176878 United States;
Fludarabine phosphate
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
G-CSF
National Heart, Lung, and Blood Institute (NHLBI)
2001 Phase 2 NCT00011505 United States;
Human Placental Derived Stem Cell
New York Medical College
2013 Phase 1 NCT01586455 United States;
Hydroxyurea
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03653338 United States;
ICL670
Novartis Pharma Services AG
2008 Phase 2 EUCTR2007-000766-20-GB Italy;United Kingdom;
Iron chelating agents
FERROKIN BIOSCIENCES INC.
2012 - EUCTR2011-005675-16-IT Canada;Italy;Lebanon;Turkey;United States;
L-leucine
Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogache
2014 Phase 2 NCT02386267 Russian Federation;
Lenalidomide
Jason Robert Gotlib
2009 Phase 1 NCT01034592 United States;
Leucine
Northwell Health
2013 Phase 1/Phase 2 NCT01362595 United States;
Leukapheresis
National Heart, Lung, and Blood Institute (NHLBI)
2001 Phase 2 NCT00011505 United States;
Melphalan
Masonic Cancer Center, University of Minnesota
1999 - NCT00290628 United States;
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
Mesenchymal Stromal Cells
Stanford University
2009 Phase 2 NCT00957931 United States;
Methotrexate
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
Methylprednisolone
Masonic Cancer Center, University of Minnesota
1999 - NCT00290628 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
Mycophenolate mofetil
Masonic Cancer Center, University of Minnesota
1999 - NCT00290628 United States;
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
Myeloablative Preparative Regimen
Masonic Cancer Center, University of Minnesota
2014 - NCT02179359 United States;
Peripheral blood stem cell transplantation
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
Radiation therapy
Masonic Cancer Center, University of Minnesota
1999 - NCT00290628 United States;
Reduced Intensity Preparative Regimen
Masonic Cancer Center, University of Minnesota
2014 - NCT02179359 United States;
Reduced Toxicity Ablative Regimen
Masonic Cancer Center, University of Minnesota
2014 - NCT02179359 United States;
Rimiducid
Bellicum Pharmaceuticals
2017 Phase 1/Phase 2 NCT03733249 Italy;Saudi Arabia;United Kingdom;
2014 Phase 2 NCT02065869 Germany;Italy;Spain;United Kingdom;United States;
Rituximab
National Heart, Lung, and Blood Institute (NHLBI)
2005 Phase 2 NCT00229619 United States;
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03653338 United States;
Rivogenlecleucel
Bellicum Pharmaceuticals
2017 Phase 1/Phase 2 NCT03733249 Italy;Saudi Arabia;United Kingdom;
SSP-004184 100 mg Capsule
Shire Development LLC
2010 Phase 2 EUCTR2010-019645-25-GB Italy;Thailand;Turkey;United Kingdom;United States;
SSP-004184 250 mg Capsule
Shire Development LLC
2010 Phase 2 EUCTR2010-019645-25-GB Italy;Thailand;Turkey;United Kingdom;United States;
SSP-004184 375 mg Capsule
Shire Development LLC
2010 Phase 2 EUCTR2010-019645-25-GB Italy;Thailand;Turkey;United Kingdom;United States;
SSP-004184 50 mg Capsule
Shire Development LLC
2010 Phase 2 EUCTR2010-019645-25-GB Italy;Thailand;Turkey;United Kingdom;United States;
SSP-004184 500 mg Capsule
Shire Development LLC
2010 Phase 2 EUCTR2010-019645-25-GB Italy;Thailand;Turkey;United Kingdom;United States;
SSP-004184AQ 100 mg Capsule
Shire Development LLC
2012 Phase 2 EUCTR2011-006322-25-GB Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
SSP-004184AQ 200 mg Capsule
Shire Development LLC
2012 Phase 2 EUCTR2011-006322-25-GB Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
SSP-004184AQ 250 mg Capsule
Shire Development LLC
2012 Phase 2 EUCTR2011-006322-25-GB Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
SSP-004184AQ 375 mg Capsule
Shire Development LLC
2012 Phase 2 EUCTR2011-006322-25-GB Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
SSP-004184AQ 50 mg Capsule
Shire Development LLC
2012 Phase 2 EUCTR2011-006322-25-GB Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
Sotatercept with prednisone boost
Northwell Health
2012 Phase 1/Phase 2 NCT01464164 United States;
Stem cell infusion
Masonic Cancer Center, University of Minnesota
2002 Phase 2/Phase 3 NCT00176852 United States;
Stem cell transplant
Masonic Cancer Center, University of Minnesota
2000 Phase 2/Phase 3 NCT00176878 United States;
Tacrolimus
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
Thiotepa
Paul Szabolcs
2018 Phase 1/Phase 2 NCT03653338 United States;
Thiotepa--escalated dose
University of Florida
2018 Phase 1/Phase 2 NCT03513328 United States;
Thiotepa--single daily dose
University of Florida
2018 Phase 1/Phase 2 NCT03513328 United States;
Total lymphoid irradiation
Masonic Cancer Center, University of Minnesota
2000 Phase 2/Phase 3 NCT00176878 United States;
Trifluoperazine
Adrianna Vlachos
2019 Phase 1/Phase 2 NCT03966053 United States;
Umbilical cord blood transplantation
Masonic Cancer Center, University of Minnesota
1999 - NCT00290628 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;